Only a week after calling it quits on a court-halted pilot program, the Trump administration is already revving the engine on how it could test out a rebate model for the 340B Drug Discount program.

While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts to transform the drug pricing program. Less than two weeks after the federal ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare ...

The Trump administration has approved eight drugmakers' rebate plans for a controversial 340B drug discount pilot program that kicks off Jan. 1. The 340B Rebate Model Pilot Program, unveiled this ...

The federal government’s recently approved 340B rebate pilot could reshape one of hospitals’ most relied-on drug discount programs, replacing upfront savings with delayed reimbursements and forcing ...

The Department of Health and Human Services is scrapping the 340B Drug Pricing Program’s rebate model, according to a Thursday court filing. Hospitals are reacting with glee, as the rebate model would ...

A federal court has blocked the implementation of the 340B rebate pilot, sparing safety-net hospitals from potential cash-flow crises and preserving upfront drug discounts for now. Revenue cycle ...

In July, the Health Resources and Services Administration announced the availability of a voluntary 340B Rebate Model Pilot Program. The program is voluntary for drugmakers, but not for hospitals, ...

HHS is weighing whether to redesign its 340B rebate model pilot program after two federal court rulings blocked its implementation and the agency formally agreed to abandon the initiative. On Feb. 13, ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog. The Trump administration announced in August ...